|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00375622 |
|
Date of registration:
|
12/09/2006 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Anti-Estrogen Therapy for Hereditary Hemorrhagic Telangiectasia A Double-Blind Placebo-Controlled Clinical Trial
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
February 2005 |
|
Target sample size:
|
60 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00375622 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
|
|
Phase:
|
Phase 2
|
|
|
Countries of recruitment
|
|
Israel
| | | | | | | |
|
Contacts
|
|
Name:
|
Eitan Yaniv, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Rabin Medical Center, Clalit Health Services |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients suffering from HHT with severe epistaxis
- Over 18 years old
Exclusion Criteria:
- Under 18 years old
- Pregnancy
- Treatment with anticoagulance
- Treatment with hormones
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Hereditary Hemorrhagic Telangiectasia
|
|
Intervention(s)
|
|
Drug: Tamoxifen
|
|
Primary Outcome(s)
|
|
Frequency of epistaxis.
|
|
Hemoglobin level.
|
|
Duration of epistaxis.
|
|
Secondary Outcome(s)
|
|
Nasal airway.
|
|
Quality of life.
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|